By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

About Thomas A. Raffin, MD:

Thomas A. Raffin, MD, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) since 1999. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Over the past two decades, Dr. Raffin has worked extensively in the health care and medical device business sectors and was an advisor to Cell Therapeutics Inc. from 1993 to 1997, Broncus Technologies from 1997 to 2004, iMedica from 1998 to 2002, and Inhale Technologies from 1998 to 2001. He cofounded Rigel Pharmaceuticals, a publicly traded company, in 1996. In 2001, he cofounded Telegraph Hill Partners, a San Francisco life sciences private equity firm as a General Partner. Dr. Raffin has been a director of the following Telegraph Hill Partners private portfolio companies: AngioScore, Confirma, Freedom Innovations, LDR Holding Corporation, Magstim, and PneumRx; and he has worked closely with Estech and Vidacare. Dr. Raffin received a BA from Stanford University and an MD from Stanford University School of Medicine and did his medical residency at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) in Boston, MA.